Zacks.com Announces That Richard Moroney Highlights the Following Stocks: Johnson & Johnson, MBNA, Delphi Financial, and Sigma-Aldrich

Business Wire, May 25, 2004

Business Editors

CHICAGO--(BUSINESS WIRE)--May 25, 2004

The Dow Transports have held their March lows. Richard Moroney explains the importance of this as it pertains to the Dow Theory, and also highlights several quality companies at good prices. Read about Johnson & Johnson (NYSE:JNJ), MBNA (NYSE:KRB), Delphi Financial (NYSE:DFG), and Sigma-Aldrich (NASDAQ:SIAL). Click here for the full story exclusively on Zacks.com: http://at.zacks.com/?id=84

Here are the highlights from the Featured Expert column:

Unlike the Dow Industrials, the Dow Transports have managed to hold their March low. If the Transports close below that low, 2750.80, the Dow Theory will shift into the bearish camp. The Dow Theory assigns equal importance to the Industrials and Transports. Unless both averages confirm a bull- or bear market signal, the primary trend is viewed as unchanged.

Some quality companies are available at good prices. Buys include

Johnson & Johnson (NYSE:JNJ) is engaged in the manufacture and sale of a broad range of products in the health care field in many countries of the world.

MBNA (NYSE:KRB) through MBNA America Bank, N.A., is an independent credit card lender and is an issuer of affinity credit cards, marketed primarily to members of associations and customers of financial institutions.

Delphi Financial (NYSE:DFG) is a holding company whose subsidiaries provide integrated employee benefit services. The Company manages all aspects of employee absence to enhance the productivity of its clients and provides the related insurance coverages: long-term and short-term disability, excess and primary workers' compensation, group life and travel accident.

Analysts' Choice: Sigma-Aldrich has growth down to a science

One of the oldest and best-known providers of laboratory products, Sigma-Aldrich (NASDAQ:SIAL) holds attractive niches in the rebounding health-sciences industry. The company has been relying on currency gains and improved profit margins to sustain growth, but near-term revenue growth should benefit from continued global expansion, acquisitions, and improved sales efforts. Margins should remain on an upswing, and internal sales growth should pick up in 2005 because of improving industry demand. At 17 times expected 2004 earnings of $3.26 per share, the stock trades in line with its five-year valuation range and at a discount to its peer-group average.

Read all of Richard Moroney's market commentaries, along with information on many more stocks, by clicking: http://at.zacks.com/?id=85

About Zacks Featured Experts

To be a successful investor you need professional advice. Experts who know what they're talking about and can help you achieve your financial goals in good markets...and especially in bad ones will help you improve your portfolio. That is why Zacks Investment Research has assembled the best investment experts in the business to offer their powerful advisory newsletters to you on all the major investment topics: Stocks, Mutual Funds, Bonds, Options, Futures etc.

Recommendations from Featured Experts Highlighted in FREE Investment Newsletter

The best way to tap into the powerful advice from these experts is through our free weekly e-mail newsletter, "Profit from the Pros". Each week we highlight several Featured Experts in this free e-mail newsletter. Get your free subscription to "Profit from the Pros" at: http://at.zacks.com/?id=86

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 to compile, analyze, and distribute investment research to both institutional and individual investors. The guiding principle behind our work is the belief that investment experts, such as brokerage analysts and investment newsletter writers, have superior knowledge about how to invest successfully. Our goal is to unlock their profitable insights for our customers. And there is no better way to enjoy this investment success, than with a FREE subscription to "Profit from the Pros" weekly e-mail newsletter. For your free newsletter, visit http://at.zacks.com/?id=87

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.